S100A9 and atrial fibrillation: These findings collectively suggest that S100A9 CKO leads to a reduction in AF, atrial structural remodeling, and cardiac fibrosis, at least partially through inhibiting the TLR4/NF-κB signaling pathways (See graphical abstract).